BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Poynard T, Calès P, Pasta L, Ideo G, Pascal J, Pagliaro L, Lebrec D; the Franco–Italian Multicenter Study Group*. Beta-Adrenergic–Antagonist Drugs in the Prevention of Gastrointestinal Bleeding in Patients with Cirrhosis and Esophageal Varices: An Analysis of Data and Prognostic Factors in 589 Patients from Four Randomized Clinical Trials. N Engl J Med 1991;324:1532-8. [DOI: 10.1056/nejm199105303242202] [Cited by in Crossref: 363] [Cited by in F6Publishing: 48] [Article Influence: 12.1] [Reference Citation Analysis]
Number Citing Articles
1 Ishida J, Konishi M, Ebner N, Springer J. Repurposing of approved cardiovascular drugs. J Transl Med 2016;14:269. [PMID: 27646033 DOI: 10.1186/s12967-016-1031-5] [Cited by in Crossref: 38] [Cited by in F6Publishing: 28] [Article Influence: 7.6] [Reference Citation Analysis]
2 Abid S, Ali S, Baig MA, Waheed AA. Is it time to replace propranolol with carvedilol for portal hypertension? World J Gastrointest Endosc 2015; 7(5): 532-539 [PMID: 25992192 DOI: 10.4253/wjge.v7.i5.532] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
3 Vadera S, Yong CWK, Gluud LL, Morgan MY. Band ligation versus no intervention for primary prevention of upper gastrointestinal bleeding in adults with cirrhosis and oesophageal varices. Cochrane Database Syst Rev 2019;6:CD012673. [PMID: 31220333 DOI: 10.1002/14651858.CD012673.pub2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
4 Bhutta AQ, Garcia-Tsao G, Reddy KR, Tandon P, Wong F, O'Leary JG, Acharya C, Banerjee D, Abraldes JG, Jones TM, Shaw J, Deng Y, Ciarleglio M, Bajaj JS. Beta-blockers in hospitalised patients with cirrhosis and ascites: mortality and factors determining discontinuation and reinitiation. Aliment Pharmacol Ther 2018;47:78-85. [PMID: 28994122 DOI: 10.1111/apt.14366] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
5 Triantos C, Kalafateli M. Primary prevention of bleeding from esophageal varices in patients with liver cirrhosis. World J Hepatol 2014; 6(6): 363-369 [PMID: 25018847 DOI: 10.4254/wjh.v6.i6.363] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 2.1] [Reference Citation Analysis]
6 Rafailidis S, Demertzidis C, Ballas K, Alatsakis M, Symeonidis N, Pavlidis T, Psarras K, Tzioufa-Asimakopoulou V, Sakadamis A. Effect of early propranolol administration on portal hypertensive gastropathy in cirrhotic rats. World J Gastroenterol 2009; 15(34): 4284-4289 [PMID: 19750571 DOI: 10.3748/wjg.15.4284] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
7 Roccarina D, Best LM, Freeman SC, Roberts D, Cooper NJ, Sutton AJ, Benmassaoud A, Plaz Torres MC, Iogna Prat L, Csenar M, Arunan S, Begum T, Milne EJ, Tapp M, Pavlov CS, Davidson BR, Tsochatzis E, Williams NR, Gurusamy KS. Primary prevention of variceal bleeding in people with oesophageal varices due to liver cirrhosis: a network meta-analysis. Cochrane Database Syst Rev 2021;4:CD013121. [PMID: 33822357 DOI: 10.1002/14651858.CD013121.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
8 Kim SG, Larson JJ, Lee JS, Therneau TM, Kim WR. Beneficial and harmful effects of nonselective beta blockade on acute kidney injury in liver transplant candidates. Liver Transpl. 2017;23:733-740. [PMID: 28187503 DOI: 10.1002/lt.24744] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
9 Hung TH, Tseng CW, Tsai CC, Lay CJ, Tsai CC. A fourfold increase of oesophageal variceal bleeding in cirrhotic patients with a history of oesophageal variceal bleeding. Singapore Med J 2016;57:511-3. [PMID: 26768323 DOI: 10.11622/smedj.2015177] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
10 Mahmoudi L, Mohammadi R, Niknam R. Economic impact of pharmacist interventions on correction of stress-related mucosal damage prophylaxis practice. Clinicoecon Outcomes Res 2019;11:111-6. [PMID: 30774401 DOI: 10.2147/CEOR.S191304] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
11 McCormick PA, O’Keefe C. Improving prognosis following a first variceal haemorrhage over four decades. Gut. 2001;49:682-685. [PMID: 11600472 DOI: 10.1136/gut.49.5.682] [Cited by in Crossref: 153] [Cited by in F6Publishing: 129] [Article Influence: 7.7] [Reference Citation Analysis]
12 Kockerling D, Nathwani R, Forlano R, Manousou P, Mullish BH, Dhar A. Current and future pharmacological therapies for managing cirrhosis and its complications. World J Gastroenterol 2019; 25(8): 888-908 [PMID: 30833797 DOI: 10.3748/wjg.v25.i8.888] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 10] [Article Influence: 10.5] [Reference Citation Analysis]
13 Yeh WS, Yang SC, Liang CM, Li YC, Tai WC, Lee CH, Yang YH, Hsu CN, Tsai TH, Chuah SK, Wu CK. The Role of Non-Selective β-Blockers in Compensated Cirrhotic Patients without Major Complications. Medicina (Kaunas) 2019;56:E14. [PMID: 31905956 DOI: 10.3390/medicina56010014] [Reference Citation Analysis]
14 Addley J, Tham TC, Cash WJ. Use of portal pressure studies in the management of variceal haemorrhage. World J Gastrointest Endosc 2012; 4(7): 281-289 [PMID: 22816007 DOI: 10.4253/wjge.v4.i7.281] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
15 Rodrigues SG, Mendoza YP, Bosch J. Beta-blockers in cirrhosis: Evidence-based indications and limitations. JHEP Rep 2020;2:100063. [PMID: 32039404 DOI: 10.1016/j.jhepr.2019.12.001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
16 O’Brien J, Triantos C, Burroughs AK. Management of varices in patients with cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10:402-412. [PMID: 23545523 DOI: 10.1038/nrgastro.2013.51] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
17 Lowe RC, Grace ND. Pharmacologic therapy for portal hyper-tension. Curr Gastroenterol Rep. 2001;3:24-29. [PMID: 11177691 DOI: 10.1007/s11894-001-0037-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
18 Qi XS, Bai M, Fan DM. Nonselective β-blockers may induce development of portal vein thrombosis in cirrhosis. World J Gastroenterol 2014; 20(32): 11463-11466 [PMID: 25170238 DOI: 10.3748/wjg.v20.i32.11463] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
19 De BK, Dutta D, Som R, Biswas PK, Pal SK, Biswas A. Hemodynamic effects of propranolol with spironolactone in patients with variceal bleeds: A randomized controlled trial. World J Gastroenterol 2008; 14(12): 1908-1913 [PMID: 18350631 DOI: 10.3748/wjg.14.1908] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
20 Sauerbruch T, Trebicka J. Future therapy of portal hypertension in liver cirrhosis - a guess. F1000Prime Rep. 2014;6:95. [PMID: 25374673 DOI: 10.12703/P6-95] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 1.9] [Reference Citation Analysis]
21 Luigiano C, Iabichino G, Judica A, Virgilio C, Peta V, Abenavoli L. Role of endoscopy in management of gastrointestinal complications of portal hypertension. World J Gastrointest Endosc 2015; 7(1): 1-12 [PMID: 25610530 DOI: 10.4253/wjge.v7.i1.1] [Cited by in CrossRef: 4] [Article Influence: 0.7] [Reference Citation Analysis]
22 Qi XS, Bao YX, Bai M, Xu WD, Dai JN, Guo XZ. Nonselective beta-blockers in cirrhotic patients with no or small varices: A meta-analysis. World J Gastroenterol 2015; 21(10): 3100-3108 [PMID: 25780311 DOI: 10.3748/wjg.v21.i10.3100] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]
23 Zacharias AP, Jeyaraj R, Hobolth L, Bendtsen F, Gluud LL, Morgan MY. Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices. Cochrane Database Syst Rev. 2018;10:CD011510. [PMID: 30372514 DOI: 10.1002/14651858.cd011510.pub2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
24 Lebrec D. Drug therapy for portal hypertension. Gut 2001;49:441-2. [PMID: 11511569 DOI: 10.1136/gut.49.3.441] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Lim N, Desarno MJ, Lidofsky SD, Ganguly E. Hospitalization for variceal hemorrhage in an era with more prevalent cirrhosis. World J Gastroenterol 2014; 20(32): 11326-11332 [PMID: 25170218 DOI: 10.3748/wjg.v20.i32.11326] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
26 Seo YS, Kim YH, Ahn SH, Yu SK, Baik SK, Choi SK, Heo J, Hahn T, Yoo TW, Cho SH. Clinical features and treatment outcomes of upper gastrointestinal bleeding in patients with cirrhosis. J Korean Med Sci. 2008;23:635-643. [PMID: 18756050 DOI: 10.3346/jkms.2008.23.4.635] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
27 Hu L, Su L, Dong Z, Wu Y, Lv Y, George J, Wang J. AMPK agonist AICAR ameliorates portal hypertension and liver cirrhosis via NO pathway in the BDL rat model. J Mol Med (Berl) 2019;97:423-34. [PMID: 30721324 DOI: 10.1007/s00109-019-01746-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
28 Poynard T, Lebray P, Ingiliz P, Varaut A, Varsat B, Ngo Y, Norha P, Munteanu M, Drane F, Messous D. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest). BMC Gastroenterol. 2010;10:40. [PMID: 20412588 DOI: 10.1186/1471-230x-10-40] [Cited by in Crossref: 123] [Cited by in F6Publishing: 38] [Article Influence: 11.2] [Reference Citation Analysis]
29 Persson EC, Quraishi SM, Welzel TM, Carreon JD, Gridley G, Graubard BI, McGlynn KA. Risk of liver cancer among US male veterans with cirrhosis, 1969-1996. Br J Cancer 2012;107:195-200. [PMID: 22588556 DOI: 10.1038/bjc.2012.193] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
30 Riley TR, Smith JP. Preventive care in chronic liver disease. J Gen Intern Med 1999;14:699-704. [PMID: 10571719 DOI: 10.1046/j.1525-1497.1999.11188.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
31 Stanley AJ, Bouchier IA, Hayes PC. Acute effect of propranolol and isosorbide-5-mononitrate administration on renal blood flow in cirrhotic patients. Gut 1998;42:283-7. [PMID: 9536956 DOI: 10.1136/gut.42.2.283] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
32 Kumar A, Sharma P, Anikhindi SA, Prajapati R, Agarwal R, Sharma B, Bansal N, Singla V, Arora A. Can Non-Selective Beta-Blockers (NSBBs) Prevent Enlargement of Small Esophageal Varices in Patients with Cirrhosis? A Meta-analysis. J Clin Exp Hepatol. 2017;7:275-283. [PMID: 29234190 DOI: 10.1016/j.jceh.2017.09.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
33 Pfisterer N, Unger LW, Reiberger T. Clinical algorithms for the prevention of variceal bleeding and rebleeding in patients with liver cirrhosis. World J Hepatol 2021; 13(7): 731-746 [PMID: 34367495 DOI: 10.4254/wjh.v13.i7.731] [Reference Citation Analysis]
34 Blasco-Algora S, Masegosa-Ataz J, Alonso S, Gutiérrez ML, Fernández-Rodriguez C. Non-selective β-blockers in advanced cirrhosis: a critical review of the effects on overall survival and renal function. BMJ Open Gastroenterol 2016;3:e000104. [PMID: 28074149 DOI: 10.1136/bmjgast-2016-000104] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
35 Sarin SK. Long term management of oesophageal varices. Drugs 1992;44 Suppl 2:56-69; discussion 70-2. [PMID: 1385070 DOI: 10.2165/00003495-199200442-00007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
36 Yoon KT, Liu H, Lee SS. β-blockers in advanced cirrhosis: More friend than enemy. Clin Mol Hepatol 2021;27:425-36. [PMID: 33317244 DOI: 10.3350/cmh.2020.0234] [Reference Citation Analysis]
37 Aithal GP, Palaniyappan N, China L, Härmälä S, Macken L, Ryan JM, Wilkes EA, Moore K, Leithead JA, Hayes PC, O'Brien AJ, Verma S. Guidelines on the management of ascites in cirrhosis. Gut 2021;70:9-29. [PMID: 33067334 DOI: 10.1136/gutjnl-2020-321790] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 16.0] [Reference Citation Analysis]
38 Gunarathne LS, Rajapaksha H, Shackel N, Angus PW, Herath CB. Cirrhotic portal hypertension: From pathophysiology to novel therapeutics. World J Gastroenterol 2020; 26(40): 6111-6140 [PMID: 33177789 DOI: 10.3748/wjg.v26.i40.6111] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
39 Merkel C, Montagnese S, Amodio P. Primary prophylaxis of bleeding from esophageal varices in cirrhosis. J Clin Exp Hepatol 2013;3:198-203. [PMID: 25755501 DOI: 10.1016/j.jceh.2013.08.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
40 Coşar AM, Yakar T, Serin E, Özer B, Kayaselçuk F. The relationship between fibrosis and nodule structure and esophageal varices. Turk J Gastroenterol 2019;30:624-9. [PMID: 31290750 DOI: 10.5152/tjg.2019.18665] [Reference Citation Analysis]
41 Kuo SZ, Lizaola B, Hayssen H, Lai JC. Beta-blockers and physical frailty in patients with end-stage liver disease. World J Gastroenterol 2018; 24(33): 3770-3775 [PMID: 30197482 DOI: 10.3748/wjg.v24.i33.3770] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
42 Samonakis DN, Triantos CK, Thalheimer U, Patch DW, Burroughs AK. Management of portal hypertension. Postgrad Med J. 2004;80:634-641. [PMID: 15537846 DOI: 10.1136/pgmj.2004.020446] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
43 Sarin SK, Kumar A, Angus PW, Baijal SS, Chawla YK, Dhiman RK, Janaka de Silva H, Hamid S, Hirota S, Hou MC. Primary prophylaxis of gastroesophageal variceal bleeding: consensus recommendations of the Asian Pacific Association for the Study of the Liver. Hepatol Int. 2008;2:429-439. [PMID: 19669318 DOI: 10.1007/s12072-008-9096-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
44 Mura VL, Tosetti G, Primignani M, Salerno F. Use of non-selective beta blockers in cirrhosis: The evidence we need before closing (or not) the window. World J Gastroenterol 2015; 21(8): 2265-2268 [PMID: 25741132 DOI: 10.3748/wjg.v21.i8.2265] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
45 Shim KY, Eom YW, Kim MY, Kang SH, Baik SK. Role of the renin-angiotensin system in hepatic fibrosis and portal hypertension. Korean J Intern Med. 2018;33:453-461. [PMID: 29462546 DOI: 10.3904/kjim.2017.317] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 10.7] [Reference Citation Analysis]
46 Sarin SK, Wadhawan M, Gupta R, Shahi H. Evaluation of endoscopic variceal ligation (EVL) versus propanolol plus isosorbide mononitrate/nadolol (ISMN) in the prevention of variceal rebleeding: comparison of cirrhotic and noncirrhotic patients. Dig Dis Sci. 2005;50:1538-1547. [PMID: 16110851 DOI: 10.1007/s10620-005-2877-1] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
47 Zaccherini G, Tufoni M, Bernardi M, Caraceni P. Prevention of Cirrhosis Complications: Looking for Potential Disease Modifying Agents. J Clin Med 2021;10:4590. [PMID: 34640608 DOI: 10.3390/jcm10194590] [Reference Citation Analysis]
48 Garcia-Pagán JC. Portal hypertension: Nonselective β-blockers in patients with refractory ascites. Nat Rev Gastroenterol Hepatol 2011;8:10-1. [PMID: 21119614 DOI: 10.1038/nrgastro.2010.185] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]